PCOS and Leiomyosarcoma Association

Understanding PCOS

PCOS is the most common endocrine disorder affecting 8-13% of women of reproductive age according to the Rotterdam criteria 1
PCOS involves insulin resistance, hyperandrogenemia, and metabolic dysfunction regardless of body mass index 1
The prevalence of PCOS in patients with temporal lobe epilepsy has been found to be between 10-25% even without antiepileptic drug use 2

Leiomyosarcoma is a rare malignant tumor, comprising only 0.1% of all uterine tumors 3
These malignancies are more common in older, postmenopausal women, with 1.7% of women undergoing hysterectomy for leiomyomata in their seventh decade of life having leiomyosarcoma 3
Leiomyosarcoma is diagnosed based on histologic criteria including increased numbers of mitoses, cellular pleomorphism, and thrombotic degeneration 3

Leiomyomata represent benign sex steroid-responsive clonal expansions of individual smooth uterine muscle tumors originating from myometrial cells 5
Approximately one-third of leiomyomas have clonal chromosomal aberrations, but these are not consistent between individual leiomyomata, even in the same woman 4
The molecular evidence does not suggest a progression from benign leiomyomata to leiomyosarcoma 4
Myometrial cells become neoplastic due to complex interactions of genetic mutation, endogenous sex-steroid production, reproductive patterns, and environmental exposures 4

Women with PCOS should be screened for type 2 diabetes and glucose intolerance with fasting glucose levels followed by a two-hour glucose tolerance test 6
Screening for dyslipidemia is recommended in all women with PCOS 6
Management should focus on addressing the metabolic and hormonal abnormalities associated with PCOS to reduce overall health risks 1